Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-Label Single-Dose Study to Assess the Pharmacokinetics and Safety of YZJ-1139 in Subjects With Severe Renal Impairment and Renal Impairment

NCT06671444 is registered in ClinicalTrials.gov with Shanghai Haiyan Pharmaceutical Technology Co., Ltd. as lead sponsor.

NCT NCT06671444
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06671444 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-Label Single-Dose Study to Assess the Pharmacokinetics and Safety of YZJ-1139 in Subjects With Severe Renal Impairment and Renal Impairment
Lead sponsor
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
June 3, 2024
Completion date
November 6, 2024
Enrollment
16 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

insomnia, renal impairment